CA3093919A1 - Gene-regulating compositions and methods for improved immunotherapy - Google Patents
Gene-regulating compositions and methods for improved immunotherapy Download PDFInfo
- Publication number
- CA3093919A1 CA3093919A1 CA3093919A CA3093919A CA3093919A1 CA 3093919 A1 CA3093919 A1 CA 3093919A1 CA 3093919 A CA3093919 A CA 3093919A CA 3093919 A CA3093919 A CA 3093919A CA 3093919 A1 CA3093919 A1 CA 3093919A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- immune effector
- nos
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000009169 immunotherapy Methods 0.000 title description 3
- 230000001976 improved effect Effects 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 381
- 210000004027 cell Anatomy 0.000 claims abstract description 302
- 239000012642 immune effector Substances 0.000 claims abstract description 278
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 278
- 230000006870 function Effects 0.000 claims abstract description 160
- 230000014509 gene expression Effects 0.000 claims abstract description 144
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 67
- 239000012636 effector Substances 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 108091007433 antigens Proteins 0.000 claims abstract description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 230000004048 modification Effects 0.000 claims abstract description 4
- 238000012986 modification Methods 0.000 claims abstract description 4
- 108700019146 Transgenes Proteins 0.000 claims abstract description 3
- 230000002062 proliferating effect Effects 0.000 claims abstract description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 396
- 108020005004 Guide RNA Proteins 0.000 claims description 278
- 230000008685 targeting Effects 0.000 claims description 189
- -1 CAIM2 Proteins 0.000 claims description 182
- 150000007523 nucleic acids Chemical class 0.000 claims description 140
- 101100165236 Homo sapiens BCOR gene Proteins 0.000 claims description 126
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 claims description 126
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 claims description 120
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 120
- 108020004459 Small interfering RNA Proteins 0.000 claims description 120
- 102100021247 BCL-6 corepressor Human genes 0.000 claims description 118
- 239000004055 small Interfering RNA Substances 0.000 claims description 106
- 239000002773 nucleotide Substances 0.000 claims description 103
- 125000003729 nucleotide group Chemical group 0.000 claims description 102
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 91
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 91
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 91
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 91
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 91
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 91
- 102000017578 LAG3 Human genes 0.000 claims description 91
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 91
- 108700009171 B-Cell Lymphoma 3 Proteins 0.000 claims description 88
- 102100021570 B-cell lymphoma 3 protein Human genes 0.000 claims description 88
- 101150072667 Bcl3 gene Proteins 0.000 claims description 88
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 claims description 88
- 101000742854 Homo sapiens Roquin-1 Proteins 0.000 claims description 88
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims description 88
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 88
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims description 88
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims description 88
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 claims description 88
- 102100038043 Roquin-1 Human genes 0.000 claims description 88
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims description 88
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims description 88
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims description 88
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 88
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 88
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims description 88
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims description 88
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 85
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 85
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims description 85
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 85
- 101000761581 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform Proteins 0.000 claims description 82
- 102100024927 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform Human genes 0.000 claims description 82
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 claims description 80
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 77
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 77
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 claims description 74
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims description 65
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims description 65
- 230000002829 reductive effect Effects 0.000 claims description 65
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 58
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 58
- 102100023882 Endoribonuclease ZC3H12A Human genes 0.000 claims description 57
- 101000976212 Homo sapiens Endoribonuclease ZC3H12A Proteins 0.000 claims description 56
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 claims description 55
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims description 55
- 101000663000 Homo sapiens TNFAIP3-interacting protein 1 Proteins 0.000 claims description 51
- 102100037667 TNFAIP3-interacting protein 1 Human genes 0.000 claims description 51
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 50
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 50
- 230000000415 inactivating effect Effects 0.000 claims description 50
- 230000035772 mutation Effects 0.000 claims description 50
- 102000039446 nucleic acids Human genes 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 39
- 102100030299 Cysteine-rich hydrophobic domain-containing protein 2 Human genes 0.000 claims description 37
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 claims description 37
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 claims description 37
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 claims description 37
- 101000991100 Homo sapiens Cysteine-rich hydrophobic domain-containing protein 2 Proteins 0.000 claims description 37
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 claims description 37
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 claims description 37
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 claims description 37
- 101000577540 Homo sapiens Neuropilin-1 Proteins 0.000 claims description 37
- 101000974015 Homo sapiens Nucleosome assembly protein 1-like 1 Proteins 0.000 claims description 37
- 101000992283 Homo sapiens Optineurin Proteins 0.000 claims description 37
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 claims description 37
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 claims description 37
- 102100025858 RNA-binding protein 39 Human genes 0.000 claims description 37
- 102100020706 WD repeat-containing protein 6 Human genes 0.000 claims description 37
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims description 36
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims description 36
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims description 36
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 claims description 36
- 101000866298 Homo sapiens Transcription factor E2F8 Proteins 0.000 claims description 36
- 102100031555 Transcription factor E2F8 Human genes 0.000 claims description 36
- 101000601770 Homo sapiens Protein polybromo-1 Proteins 0.000 claims description 33
- 102100037516 Protein polybromo-1 Human genes 0.000 claims description 33
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims description 32
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims description 32
- 102100037545 Semaphorin-7A Human genes 0.000 claims description 26
- 102100025579 Calmodulin-2 Human genes 0.000 claims description 25
- 230000002255 enzymatic effect Effects 0.000 claims description 25
- 108010042407 Endonucleases Proteins 0.000 claims description 22
- 102100028762 Neuropilin-1 Human genes 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 12
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 10
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 10
- 102000027596 immune receptors Human genes 0.000 claims description 10
- 108091008915 immune receptors Proteins 0.000 claims description 10
- 101100149240 Danio rerio sema4e gene Proteins 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000003007 single stranded DNA break Effects 0.000 claims description 7
- 101000735354 Homo sapiens Poly(rC)-binding protein 1 Proteins 0.000 claims description 6
- 102100035880 Max-interacting protein 1 Human genes 0.000 claims description 6
- 101710112905 Max-interacting protein 1 Proteins 0.000 claims description 6
- 102100034960 Poly(rC)-binding protein 1 Human genes 0.000 claims description 6
- 238000010459 TALEN Methods 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 5
- 101150030897 pstP gene Proteins 0.000 claims description 5
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 4
- 230000037433 frameshift Effects 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 108091033409 CRISPR Proteins 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 3
- 108700011259 MicroRNAs Proteins 0.000 claims description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 3
- 230000005975 antitumor immune response Effects 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 230000003833 cell viability Effects 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000002679 microRNA Substances 0.000 claims description 3
- 238000010361 transduction Methods 0.000 claims description 3
- 230000026683 transduction Effects 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims 48
- 102100022389 Nucleosome assembly protein 1-like 1 Human genes 0.000 claims 24
- 101000854918 Homo sapiens WD repeat-containing protein 6 Proteins 0.000 claims 21
- 101000807596 Homo sapiens Orotidine 5'-phosphate decarboxylase Proteins 0.000 claims 20
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 claims 20
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 claims 18
- 101000984150 Homo sapiens Calmodulin-2 Proteins 0.000 claims 18
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 claims 18
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 claims 18
- 101000739767 Homo sapiens Semaphorin-7A Proteins 0.000 claims 13
- 102100031780 Endonuclease Human genes 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 4
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000004568 DNA-binding Effects 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101100539472 Naegleria gruberi UMP gene Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 abstract description 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract description 3
- 108091008874 T cell receptors Proteins 0.000 abstract description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 36
- 102000048854 Friend leukemia integration 1 transcription factor Human genes 0.000 description 16
- 108010080989 Proto-Oncogene Protein c-fli-1 Proteins 0.000 description 16
- 101710083185 WD repeat-containing protein 6 Proteins 0.000 description 16
- 102000004533 Endonucleases Human genes 0.000 description 12
- 101710164734 Calmodulin-2 Proteins 0.000 description 7
- 238000012546 transfer Methods 0.000 description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 3
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 101100327050 Caenorhabditis elegans cbp-1 gene Proteins 0.000 description 1
- 101710112715 Endoribonuclease ZC3H12A Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4728—Calcium binding proteins, e.g. calmodulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0201—Orotate phosphoribosyltransferase (2.4.2.10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01023—Orotidine-5'-phosphate decarboxylase (4.1.1.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643578P | 2018-03-15 | 2018-03-15 | |
| US201862643598P | 2018-03-15 | 2018-03-15 | |
| US201862643587P | 2018-03-15 | 2018-03-15 | |
| US201862643597P | 2018-03-15 | 2018-03-15 | |
| US62/643,578 | 2018-03-15 | ||
| US62/643,587 | 2018-03-15 | ||
| US62/643,598 | 2018-03-15 | ||
| US62/643,597 | 2018-03-15 | ||
| US201862692100P | 2018-06-29 | 2018-06-29 | |
| US201862692010P | 2018-06-29 | 2018-06-29 | |
| US201862692019P | 2018-06-29 | 2018-06-29 | |
| US62/692,010 | 2018-06-29 | ||
| US62/692,100 | 2018-06-29 | ||
| US62/692,019 | 2018-06-29 | ||
| US201862768448P | 2018-11-16 | 2018-11-16 | |
| US201862768458P | 2018-11-16 | 2018-11-16 | |
| US201862768443P | 2018-11-16 | 2018-11-16 | |
| US201862768428P | 2018-11-16 | 2018-11-16 | |
| US62/768,448 | 2018-11-16 | ||
| US62/768,443 | 2018-11-16 | ||
| US62/768,428 | 2018-11-16 | ||
| US62/768,458 | 2018-11-16 | ||
| US201962804265P | 2019-02-12 | 2019-02-12 | |
| US62/804,265 | 2019-02-12 | ||
| PCT/US2019/022365 WO2019178421A1 (en) | 2018-03-15 | 2019-03-14 | Gene-regulating compositions and methods for improved immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3093919A1 true CA3093919A1 (en) | 2019-09-19 |
Family
ID=67906919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3093919A Pending CA3093919A1 (en) | 2018-03-15 | 2019-03-14 | Gene-regulating compositions and methods for improved immunotherapy |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR20200130826A (ja) |
| CN (1) | CN112040987A (ja) |
| AU (1) | AU2019236204A1 (ja) |
| CA (1) | CA3093919A1 (ja) |
| WO (1) | WO2019178421A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109517820B (zh) | 2017-09-20 | 2021-09-24 | 北京宇繁生物科技有限公司 | 一种靶向HPK1的gRNA以及HPK1基因编辑方法 |
| JP2023502780A (ja) * | 2019-11-25 | 2023-01-25 | ケーエスキュー セラピューティクス， インコーポレイテッド | 腫瘍浸潤リンパ球の活性化及び増殖方法 |
| CN110777147A (zh) * | 2019-11-29 | 2020-02-11 | 上海科技大学 | 一种ikzf3基因沉默的t细胞及其应用 |
| KR20230074515A (ko) | 2020-09-23 | 2023-05-30 | 크리스퍼 테라퓨틱스 아게 | 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포 |
| TW202237822A (zh) | 2020-11-19 | 2022-10-01 | 大陸商蘇州沙礫生物科技有限公司 | 腫瘤浸潤淋巴細胞的培養方法及其用途 |
| EP4281188A2 (en) * | 2021-01-19 | 2023-11-29 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Gene activation targets for enhanced human t cell function |
| US20240285685A1 (en) * | 2021-05-20 | 2024-08-29 | WuXi Biologics Ireland Limited | Genetically modified nk cells and uses thereof |
| WO2023011433A1 (zh) * | 2021-08-03 | 2023-02-09 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| CN113750218B (zh) * | 2021-08-10 | 2022-05-20 | 南通市肿瘤医院 | 多肽zc3h12a及其突变体在制备抗肝癌药物中的应用 |
| WO2023082640A1 (zh) * | 2021-11-10 | 2023-05-19 | 清华大学 | 增强免疫细胞持久性的方法 |
| CN118401651A (zh) * | 2022-01-29 | 2024-07-26 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| WO2023225665A1 (en) * | 2022-05-19 | 2023-11-23 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
| CN118696123A (zh) * | 2022-07-10 | 2024-09-24 | 清华大学 | 经修饰的免疫细胞 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999014321A1 (en) * | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| US8894996B2 (en) * | 2009-02-27 | 2014-11-25 | Osaka University | Immunoadjuvant composition and use thereof |
| US20150218636A1 (en) * | 2012-04-12 | 2015-08-06 | Aarhus Universitet | Mutations In Calmodulin Genes |
| US20180161369A1 (en) * | 2015-05-29 | 2018-06-14 | Fred Hutchinson Cancer Research Center | Compositions for cellular immunotherapy |
| CA2986314C (en) * | 2015-06-30 | 2024-04-23 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| EP3341006A4 (en) * | 2015-08-28 | 2019-03-13 | BioIncept LLC | COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE |
| WO2017048995A1 (en) * | 2015-09-15 | 2017-03-23 | Mirimus, Inc. | Inducible crispr/cas9 and rnai systems and methods of use |
| US11020430B2 (en) * | 2015-11-04 | 2021-06-01 | Emory University | Immune cells with DNMT3A gene modifications and methods related thereto |
-
2019
- 2019-03-14 AU AU2019236204A patent/AU2019236204A1/en active Pending
- 2019-03-14 CN CN201980019421.XA patent/CN112040987A/zh active Pending
- 2019-03-14 CA CA3093919A patent/CA3093919A1/en active Pending
- 2019-03-14 WO PCT/US2019/022365 patent/WO2019178421A1/en active Application Filing
- 2019-03-14 KR KR1020207026518A patent/KR20200130826A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112040987A (zh) | 2020-12-04 |
| KR20200130826A (ko) | 2020-11-20 |
| AU2019236204A1 (en) | 2020-10-08 |
| WO2019178421A1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11608500B2 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| US20230088186A1 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| US12084682B2 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| US20200347386A1 (en) | Combination gene targets for improved immunotherapy | |
| CA3093919A1 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| US11332713B2 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| US12123021B2 (en) | Gene-regulating compositions and methods for improved immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231215 |